Role of NK Cells in Progression and Treatment of Multiple Myeloma
Frontiers in Bioscience-Landmark · 25.04.2025 · 30 (4)
DOI: 10.31083/fbl26205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 25.04.2025. Verfasst von Iman Chanchiri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Odense University Hospital, 5000 Odense, Denmark. Hauptthemen laut MEDLINE: Killer Cells, Natural, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) is a haematological malignancy originating from terminally differentiated B cells, resulting in significant morbidity and mortality. Currently, MM is regarded as an incurable disease, often exhibiting a relapse-remitting pattern that necessitates multiple lines of therapy. It is now well-established that ineffective immunosurveillance plays a critical role in the progression of MM. Consequently, strategies that redirect immune effector cells against MM have emerged as effective treatment modalities, particularly in cases where standard care therapies fail. T cell-based immunotherapy has gained considerable attention in ongoing clinical trials; however, natural killer (NK) cells, known for their ability to execute cytotoxicity against infected and malignant cells with precision, may offer complementary therapeutic advantages over T cells and possess untapped therapeutic potential. This review seeks to introduce readers to the significance of NK cell-mediated immunosurveillance in the context of MM, explore the potential benefits of redirecting NK cells against MM, and illustrate how current treatment strategies are often reliant on the functionality of NK cells. Most importantly, new promising mechanisms of harnessing NK cell-based immunity against MM are reviewed and put into a clinical perspective to highlight their implications for patient treatment and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, Odense University Hospital, 5000 Odense, Denmark.
- Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, 5000 Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark.
- Department of Clinical Immunology, Odense University Hospital, 5000 Odense, Denmark.
- Centre for Innovative Medical Technology (CIMT), Odense University Hospital, 5000 Odense, Denmark.
Zitieren
APA
Chanchiri, I., Christensen, E. B., Abildgaard, N., Barington, T., Lund, T., & Krejcik, J. (2025). Role of NK Cells in Progression and Treatment of Multiple Myeloma. Frontiers in Bioscience-Landmark, 30(4). https://doi.org/10.31083/fbl26205
Vancouver
Chanchiri I, Christensen EB, Abildgaard N, Barington T, Lund T, Krejcik J. Role of NK Cells in Progression and Treatment of Multiple Myeloma. Frontiers in Bioscience-Landmark. 2025;30(4). doi:10.31083/fbl26205
BibTeX
@article{Chanchiri2025,
author = {Chanchiri, Iman and Christensen, Emil Birch and Abildgaard, Niels and Barington, Torben and Lund, Thomas and Krejcik, Jakub},
title = {Role of NK Cells in Progression and Treatment of Multiple Myeloma},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
volume = {30},
number = {4},
doi = {10.31083/fbl26205}
}
EUVIMED